共 50 条
Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials
被引:29
|作者:
Zoccali, Carmine
[1
]
Blankestijn, Peter J.
[2
]
Bruchfeld, Annette
[3
]
Capasso, Giovambattista
[4
]
Fliser, Danilo
[5
]
Fouque, Denis
[6
]
Goumenos, Dimitrios
[7
]
Ketteler, Markus
[8
]
Massy, Ziad
[9
]
Rychlik, Ivan
[10
]
Jose Soler, Maria
[11
]
Stevens, Kate
[12
]
Spasovski, Goce
[13
]
Wanner, Christoph
[14
]
机构:
[1] Osped Riuniti Reggio Calabria, CNR IFC, Reggio Di Calabria, Italy
[2] Univ Med Ctr, Dept Nephrol, Utrecht, Netherlands
[3] Karolinska Univ Hosp, Dept Renal Med, Stockholm, Sweden
[4] Univ Campania Luigi Vanvitelli, Dept Nephrol, Naples, Italy
[5] Univ Med Ctr, Internal Med Renal & Hypertens Dis 4, Homburg, Germany
[6] Ctr Hosp Lyon Sud, Dept Nephrol Dialysis Nutr, Pierre Banite, France
[7] Patras Univ Hosp, Dept Nephrol & Renal Transplantat, Patras, Greece
[8] Nephrol Klin Klinikum Coburg, Coburg, Germany
[9] Paris Ile de France West Univ UVSQ, Ambroise Pare Hosp, Div Nephrol, Villejuif, France
[10] Charles Univ Prague, Fac Med 3, Dept Internal Med 1, Prague, Czech Republic
[11] Hosp Univ Vall dHebron, Dept Nephrol, Vall dHebron Res Inst VHIR, Nephrol Res Grp, Barcelona, Spain
[12] Queen Elizabeth Univ Hosp, Glasgow Renal & Transplant Unit, Glasgow, Lanark, Scotland
[13] Univ Skopje, Med Fac, Dept Nephrol, Skopje, North Macedonia
[14] Univ Wurzburg, Div Nephrol, Wurzburg, Germany
关键词:
cardiovascular;
CKD;
clinical trial;
diabetes mellitus;
guidelines;
CANCER;
REPRESENTATION;
OUTCOMES;
D O I:
10.1093/ndt/gfz023
中图分类号:
R3 [基础医学];
R4 [临床医学];
学科分类号:
1001 ;
1002 ;
100602 ;
摘要:
The exclusion of chronic kidney disease (CKD) patients from clinical trials-particularly cardiovascular trials-remains a long-standing, unsolved problem, which prevents the optimization of clinical care in these patients. The situation recalls the insufficient recruitment of women in cardiovascular trials until the 1980s, a problem that was only resolved following regulatory interventions. Regulatory agencies are in a unique position to promote recruitment of CKD patients in clinical trials. The main stakeholders, namely patients' associations and scientific societies, should make major lobbying efforts to persuade these agencies that the issue is an absolute public health priority.
引用
收藏
页码:1112 / 1114
页数:3
相关论文